Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Cantor Fitzgerald
McKesson
Deloitte
Farmers Insurance
Chubb
Colorcon
Chinese Patent Office
Mallinckrodt

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,639,071

« Back to Dashboard

Which drugs does patent 6,639,071 protect, and when does it expire?

Patent 6,639,071 protects SUSTIVA and ATRIPLA and is included in three NDAs.

Protection for SUSTIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in twenty countries.
Summary for Patent: 6,639,071
Title: Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one
Abstract:The instant invention describes a method for crystallizing (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one from a solvent and anti-solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40.degree. C. and 50.degree. C.
Inventor(s): Crocker; Louis S. (Belle Mead, NJ), Kukura, II; Joseph L. (Somerset, NJ), Thompson; Andrew S. (Mountainside, NJ), Stelmach; Christine (Westfield, NJ), Young; Steven D. (Lansdale, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:10/000,537
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 6,639,071

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gilead ATRIPLA efavirenz; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 021937-001 Jul 12, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz TABLET;ORAL 021360-001 Feb 1, 2002 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz TABLET;ORAL 021360-002 Feb 1, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,639,071

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,965,729 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent ➤ Subscribe
6,939,964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,639,071

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia 105599 ➤ Subscribe
Poland 197740 ➤ Subscribe
Poland 334478 ➤ Subscribe
New Zealand 336510 ➤ Subscribe
Norway 320128 ➤ Subscribe
Norway 993779 ➤ Subscribe
South Korea 100573192 ➤ Subscribe
South Korea 20000070735 ➤ Subscribe
Japan 2017061575 ➤ Subscribe
Japan 2013139484 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Cantor Fitzgerald
Healthtrust
Daiichi Sankyo
Moodys
Federal Trade Commission
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot